Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMX-67 (febuxostat) long-term extension in hyperuricemic pediatric patients
jRCT2080224845Phase 2Completed
- Sponsor
- Teijin Pharma
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of febuxostat in hyperuricemia and gout, sponsored by Teijin Pharma. Primary endpoints: Safety over 52 weeks, Efficacy (serum uric acid reduction and maintenance) and 1 more. Started Aug 2019; status: completed.
02
Drugs
febuxostat
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on jRCT2080224845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224845.